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There is a high incidence of thyroid dysfunction during pregnancy resulting in adverse maternal (miscarriages, anaemia
in pregnancy, preeclampsia, abruptio placenta and post-partum haemorrhage) and fetal eﬀects (premature birth, low birth
weight, increased neonatal respiratory distress) which may justify screening for thyroid function during early pregnancy with
interventional levothyroxine therapy for thyroid hypofunction. There is a greater prevalence of subclinical hypothyroidism in
women with delivery before 32 weeks and there is even an association between thyroid autoimmunity and adverse obstetric
outcome, which is independent of thyroid function. Higher maternal TSH levels even within the normal reference range are
associated with an increased risk of miscarriages, fetal and neonatal distress and preterm delivery. There are few prospective
randomisedtrialsto substantiatethebeneﬁt ofscreeningandtherecentlyreported CATSstudy didnotshowabeneﬁt inchildIQat
age 3 years. Nevertheless there seems to be a case for screening to prevent adverse obstetric outcomes. The clinical epidemiological
evidence base does not justify universal screening at the present time. However, it is probable that more evidence will be produced
which may alter this view in the future.
1.Introduction
Thyroid disorders are common. The prevalence of hyperthy-
roidism is around 5 per 1000 in women and overt hypothy-
roidism about 3 per 1000 in women. Subclinical hypothy-
roidism has a prevalence in child bearing age women in
iodine suﬃcient areas of between 4 and 8%. As the condi-
tions are generally much more common in the female it is to
be expected that they will appear during pregnancy. During
the last decade there has been an increasing appreciation of
the incidence of thyroid dysfunction during pregnancy as
well as the resultant adverse maternal and fetal eﬀects [1–
3] .I nt h eh o p et h a tm a n yo ft h e s ea d v e r s ee ﬀects could be
prevented or ameliorated by early detection and appropriate
treatment the proposal to implement screening for thyroid
function during pregnancy deserves consideration.
2.ScreeningforDisease
Medical screening is the systematic application of a test or
inquiry to identify individuals at suﬃcient risk of a speciﬁc
disorder to beneﬁt from further investigation or direct pre-
ventive action [4]. The requirements for a justiﬁable screen-
ing test are shown in Table 1.
It will be apparent that screening a population must be
considered very carefully in respect of the condition being
screened for, the eﬀectiveness (and safety) of any interven-
tion, and the potential anxiety of the patient. If the eﬀec-
tiveness is not known with certainty then evidence should be
sought, usually in the form of a randomised trial.
3.Does Thyroid Screeningin PregnancyMeet
the AboveCriteriaforScreening?
The prevalence of Graves’ disease is approximately 3.0/1000
withanincidenceofabout0.5/1000/year.Theprevalenceand
incidence in women during child bearing years is not known
but thyrotoxicosis is said to occur in 2/1000 pregnancies
and Graves’ disease would be expected to account for at
least 80% of these cases. While these ﬁgures are low, Graves’
hyperthyroidism can have a dramatic eﬀect on the mother2 Journal of Thyroid Research
Table 1: Justiﬁcation for screening test (adapted from Wald and
Law 2010 [4]).
(1) Well-deﬁned disorder with known incidence/prevalence.
(2) Medically important disorder.
(3) Screening test simple and safe with established cutoﬀ values.
(4) Eﬀective treatment available.
(5) Cost of test relative to beneﬁt should be known.
(6) Adequate logistics for the testing and followup.
(7) Patient and managementacceptability.
as well as the fetus. There are signiﬁcant maternal com-
plications including miscarriage, placenta abruptio, preterm
delivery, and pre-eclampsia [5]. One to 5% of neonates
of mothers with Graves’ disease have hyperthyroidism
due to the transplacental passage of maternal stimulating
thyrotropin receptor antibodies (TRAbs) [6]. This may
occur even though the mother may be euthyroid and has
received previous treatment for Graves’ disease. Neonatal
hyperthyroidism may also be due to an activating mutation
of the TSH receptor dominantly inherited from the mother.
Transient neonatal central hypothyroidism is due to poorly
controlled Graves’ disease leading to suppression of the
fetal pituitary thyroid axis due to placental transfer of T4
[7]. Subclinical hyperthyroidism (i.e., normal circulating
concentrations of T4 and T3 but subnormal TSH levels)
occurs in approximately 1.7% of pregnant women and is not
associated with adverse pregnancy outcomes [8]. Screening
for this condition is clearly not warranted, although if a low
TSH is found the establishment of the cause will improve
obstetric outcome in a number of women [9].
In contrast to hyperthyroidism, hypothyroidism is quite
c o m m o ni np r e g n a n c y[ 10]. The incidence of subclinical
hypothyroidism (raised TSH and normal or low normal T4)
is at least 2.5%, and these women have no clinical features
and are often asymptomatic, but 50–60% will have evidence
of autoimmune thyroid disease (positive TPOAbs and or
thyroglobulin antibodies, TgAbs) in iodine-suﬃcient areas.
It should be noted however that endemic iodine deﬁciency is
the most common cause of hypothyroidism seen in pregnant
women worldwide. Overt hypothyroidism occurs in only
about 5% of all women who have a high TSH. During
the last decade, it has become apparent that untreated
maternal hypothyroidism and subclinical hypothyroidism
in pregnancy is associated with adverse fetal and obstet-
ric outcomes [11, 12]. These events include miscarriages,
anaemia in pregnancy, preeclampsia, abruptio placenta, and
postpartum haemorrhage while premature birth, low birth
weight, increased neonatal respiratory distress, and more
admissions to the neonatal intensive care unit have been
described in babies born to mothers with hypothyroidism
[13]. There is a greater prevalence of subclinical hypothy-
roidism in women with delivery before 32 weeks, and there
is even an association between thyroid autoimmunity and
adverse obstetric outcome, which is independent of thyroid
function [14]. Higher maternal TSH levels even within the
normal reference range are associated with an increased
risk of miscarriages, fetal and neonatal distress [15]a sw e l l
as preterm delivery [16]. In a prospective study, euthyroid
TPOAb+ve women who received interventional L-thyroxine
in early pregnancy had a reduced miscarriage rate and less
preterm delivery [17]. Further prospective randomised trials
are required to conﬁrm these interesting data. Of equal or
even greater importance than the above is the detrimental
eﬀect of hypothyroidism during pregnancy on fetal brain
development. The availability of thyroxine to the developing
fetal neurones is vital for their maturation and proper
function [18]. Two studies [19, 20]h a v es h o w nt h a tl o w
thyroid hormone concentrations in early gestation can be
associated with signiﬁcant decrements of IQ of the children
when tested at 7 years and 10 months, respectively. Pop
et al. [21] have also shown a signiﬁcant decrement in IQ
in children aged 5 years whose mothers were known to
have circulating anti-TPO antibodies at 32-week gestation
and were biochemically euthyroid. Moreover, as shown by
Haddow et al. [22], the 7-year-old children of women
known to be hypothyroid during gestation showed impaired
psychologicaldevelopmentcomparedtochildrenofthesame
age from carefully matched control mothers whose thyroid
function was known to be normal during pregnancy. In this
paper it is interesting that a subgroup of children whose
mothers had been receiving thyroxine for hypothyroidism
during pregnancy (albeitatinadequatedosesasevidencedby
high TSH during pregnancy) also showed some impairment
of psychological performance although not as great as
the other children. The neurodevelopmental impairment is
similar to that seen in iodine-deﬁcient areas and implies that
iodine status should be normalised in regions of deﬁciency.
However, much of the USA and parts of Europe are not
iodine deﬁcient which raises the question of routine screen-
ing of thyroid function during early pregnancy or even at
preconception. It is now appreciated that similar decrements
in mentation can be seen in iodine-deﬁcient areas as well as
iodine-suﬃcient onesthusprovidingfurtherevidenceforthe
role of thyroid hormone in fetal neurodevelopment.
Isolated hypothyroxinaemia (low FT4 and normal TSH)
either due to iodine deﬁciency or autoimmune thyroid
disease has been shown to result in lower IQ in infants and
y o u n gc h i l d r e ni nr e t r o s p e c t i v e[ 22] and prospective [23]
studies. Althoughit has been found not to be associated with
adverse perinataloutcomes[24],itisassociated withreduced
motor and intelligence performance in neonates [25]a n d
in children aged 25–30 months in a Chinese population
[26]. While treatment of overt hypothyroidism has been
shown to prevent the obstetric and neonatal complications
the evidence for treatment of subclinical hypothyroidism in
preventionislesssecure.However,inarecentscreeningstudy
where women were characterised as high risk or low risk in
terms of the chance of adverse obstetric outcome there was
a signiﬁcant reduction in these outcomes even in low-risk




The strength of evidence relating maternal hypothyroidism
to low IQ in children suggests strongly that screening thyroidJournal of Thyroid Research 3
function in early gestation with l-thyroxine intervention in
appropriate women would be beneﬁcial. In addition there is
evidence that such a strategy would be cost-eﬀective. A study
by Thung et al. [28]c o m p a r e dt h ec o s t - e ﬀectiveness of no
screening versus routine screening for subclinical hypothy-
roidism in pregnancy. The decision model demonstrated a
saving of approximately $8.3 million per 100,000 women
screened with an increment of 589.3 quality adjusted life
years. Similar results were obtained by Dosiu et al. [29]u s i n g
ad i ﬀerent screening model.
Several organisations have issued guidelines on whether
to adopt a screening strategy for thyroid function in early
pregnancy [30–32]. The most recent published recommen-
dations are from the Endocrine Society of America [33]
which do not endorse universal screening. Instead, a targeted
approach is suggested in which screening would be oﬀeredto
womenwithafamilyhistoryofthyroidorotherautoimmune
disease as well as to women with any risk factors for thyroid
dysfunction(e.g.,previousneckirradiation,previousthyroid
surgery). Although this would seem a reasonable approach
in relation to economic and logistic factors there has been
accruing evidence that a substantial number of women
with thyroid dysfunction would not be diagnosed in these
circumstances. Vaidya [34] found that targeted testing of
a previously deﬁned high-risk group who had a personal
history ofthyroid orotherautoimmunedisorders orafamily
history of thyroid disease (413 women) failed to detect 28%
of pregnant women with a TSH > 4.2mIU/L. Li et al. [26]
found that this strategy missed 36% of women with TSH
> 4.0mIU/L. In the study of Negro et al. [27], screening
“low-risk women” identiﬁed 28% with thyroid dysfunction
excluding those with just positive thyroid antibodies. The
variability seen in these data may relate to diﬀerent deﬁni-
tions of thyroid dysfunction and diﬀerent ethnicity of the
populations studied. Further work in this area is required.
At the time of writing this paper the unpublished guidelines
fromTheAmericanThyroidAssociationdidnotrecommend
screening while members from the as yet unpublished
guidelines from The American Endocrine Society guidelines
committee were divided 50/50 as to their recommendations.
At present there are no published prospective con-
trolled trials of a screening strategy assessing child IQ.
Preliminary results from a prospective randomized trial
of L-T4 treatment in women screened prior to 16-week
gestation (compared with control women not screened and
therefore not treated with L-T4), the CATS study, are now
available. The mean IQ of the two groups of children (screen
and control) was not diﬀerent. However, an on-treatment
analysis showed that the number of children with IQ > 85
born to women with subclinical hypothyroidism who were
considered to have been compliant with their T4 treatment
was signiﬁcantly less (9%) than that in the control group
(15%).
5.Conclusion
The screening criteria for subclinical hypothyroidism in
pregnancy are largely met. The condition is not rare, and
several retrospective studies imply adverse obstetric and
child neurodevelopmental outcomes. However there are few
prospective randomised trials to substantiate the beneﬁt of
screening, and the recently reported CATS study did not
show abeneﬁtinchildIQatageof 3years. Neverthelessthere
seems to be a case for screening to prevent adverse obstetric
outcomes. From the child cognitive function aspect there
should befurther studieswhere interventionisinitiated early
in the ﬁrst trimester during the course of braindevelopment.
Results of such a study being conducted by the National
Institutes of Health are awaited.
Fromtheforgoingdiscussionthisauthorbelievesthatthe
clinical epidemiological evidence base does not justify uni-
versal screening at the present time. However, it is probable
that more evidence will be produced which may alter this
view in the future.
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